Guerbet SA GBT
EURONEXT · France · Health Technology
€6.71-0.29 (-4.14%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Uniper has joined a growing list of aviation fuel buyers that have reserved future production capacity from Syzygy Plasmonics' NovaSAF™ platform, as commercial momentum behind the company's biogas-to-SAF technology continues to build.
30/09/2026 First half 2026:Revenue up 3.2%,EBITDA margin of 10.1%,and positive free cash flow of €11.1m 2026 targets revised upwards2027 financial targets confirmed in € millionsH1 2026H1 2025ChangeRevenue235.2227.9+3.2%Current EBITDA23.717.0+39.3%as % of revenue10.1%7.5%+261 bpsCurrent operating profit17.310.7+62.4%as % of revenue7.4%4.7%+269 bpsOperating profit17.19.4+81.4%Net financial result(3.6)0.15 Income tax expense(4.6)(1.2) Net income from continuing operations9.08.4+6.4%Net income from
The shareholders that have appointed the members of the nomination committee represented in aggregate 29.62 percent of all shares in the company as of 31 August 2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.